Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more
Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) - Total Assets
Latest total assets as of September 2025: CN¥17.27 Billion CNY
Based on the latest financial reports, Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) holds total assets worth CN¥17.27 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Total Assets Trend (1994–2024)
This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Asset Composition Analysis
Current Asset Composition (December 2024)
Starlake Bioscience Co Inc Zhaoqing Guangdong's total assets of CN¥17.27 Billion consist of 35.8% current assets and 64.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.1% |
| Accounts Receivable | CN¥1.05 Billion | 7.2% |
| Inventory | CN¥2.07 Billion | 14.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥680.20 Million | 4.7% |
| Goodwill | CN¥29.32 Million | 0.2% |
Asset Composition Trend (1994–2024)
This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Starlake Bioscience Co Inc Zhaoqing Guangdong's current assets represent 35.8% of total assets in 2024, a decrease from 46.3% in 1994.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is inventory at 14.3% of total assets.
Starlake Bioscience Co Inc Zhaoqing Guangdong Competitors by Total Assets
Key competitors of Starlake Bioscience Co Inc Zhaoqing Guangdong based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Starlake Bioscience Co Inc Zhaoqing Guangdong - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Starlake Bioscience Co Inc Zhaoqing Guangdong generates 1.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Starlake Bioscience Co Inc Zhaoqing Guangdong generates $6.48 in net profit.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.98 | 1.15 | 1.31 |
| Quick Ratio | 0.77 | 0.82 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-127.86 Million | CN¥ 655.50 Million | CN¥ 172.01 Million |
Starlake Bioscience Co Inc Zhaoqing Guangdong - Advanced Valuation Insights
This section examines the relationship between Starlake Bioscience Co Inc Zhaoqing Guangdong's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.42 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 1.1% |
| Total Assets | CN¥14.55 Billion |
| Market Capitalization | $990.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Starlake Bioscience Co Inc Zhaoqing Guangdong's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Starlake Bioscience Co Inc Zhaoqing Guangdong's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Starlake Bioscience Co Inc Zhaoqing Guangdong (1994–2024)
The table below shows the annual total assets of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.55 Billion | +1.15% |
| 2023-12-31 | CN¥14.38 Billion | -10.09% |
| 2022-12-31 | CN¥16.00 Billion | +546.83% |
| 2021-12-31 | CN¥2.47 Billion | +2.12% |
| 2020-12-31 | CN¥2.42 Billion | +14.45% |
| 2019-12-31 | CN¥2.12 Billion | +46.42% |
| 2018-12-31 | CN¥1.45 Billion | -0.23% |
| 2017-12-31 | CN¥1.45 Billion | -15.30% |
| 2016-12-31 | CN¥1.71 Billion | -7.25% |
| 2015-12-31 | CN¥1.84 Billion | -18.25% |
| 2014-12-31 | CN¥2.26 Billion | -13.37% |
| 2013-12-31 | CN¥2.60 Billion | -21.87% |
| 2012-12-31 | CN¥3.33 Billion | -2.62% |
| 2011-12-31 | CN¥3.42 Billion | +48.34% |
| 2010-12-31 | CN¥2.31 Billion | +54.06% |
| 2009-12-31 | CN¥1.50 Billion | +10.37% |
| 2008-12-31 | CN¥1.36 Billion | +0.56% |
| 2007-12-31 | CN¥1.35 Billion | -4.24% |
| 2006-12-31 | CN¥1.41 Billion | +3.27% |
| 2005-12-31 | CN¥1.36 Billion | +4.61% |
| 2004-12-31 | CN¥1.30 Billion | +11.34% |
| 2003-12-31 | CN¥1.17 Billion | +14.41% |
| 2002-12-31 | CN¥1.02 Billion | +2.22% |
| 2001-12-31 | CN¥1.00 Billion | -7.51% |
| 2000-12-31 | CN¥1.08 Billion | +27.80% |
| 1999-12-31 | CN¥847.38 Million | +38.06% |
| 1998-12-31 | CN¥613.79 Million | +20.14% |
| 1997-12-31 | CN¥510.92 Million | +32.59% |
| 1996-12-31 | CN¥385.33 Million | +7.24% |
| 1995-12-31 | CN¥359.32 Million | +11.34% |
| 1994-12-31 | CN¥322.72 Million | -- |